Education
About Us
Working with TipRanks
Follow Us
Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
0RG8 Stock Chart & Stats
€176.00
-€0.39(-0.20%)
At close: 4:00 PM EST
€176.00
-€0.39(-0.20%)
Day’s Range― - ―
52-Week Range€149.70 - €223.20
Previous CloseN/A
Volume2.47K
Average Volume (3M)57.59K
Market Cap
€17.46B
Enterprise Value€20.11B
Total Cash (Recent Filing)€426.10M
Total Debt (Recent Filing)€2.75B
Price to Earnings (P/E)64.5
Beta1.65
Next Earnings
Apr 23, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.12
Shares Outstanding97,330,410
10 Day Avg. Volume38,577
30 Day Avg. Volume57,592
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€235.86Price Target Upside34.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)5.05
Revenue Forecast (FY)€3.20B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From Consumables & ServicesA large share of sales comes from consumables and services, creating durable annuity-like revenues and customer stickiness. Over the next 2–6 months this supports revenue visibility and predictable cash inflows, helping fund R&D and operations despite equipment cyclicality.
Integrated Solutions And Market LeadershipLeadership in integrated bioprocess systems and single-use technologies yields strong competitive advantages: high switching costs, cross-sell potential, and deep pharma partnerships. These structural advantages sustain market share and long-term demand in growing biologics segments.
Revenue Rebound And Improved LeverageA sharp TTM revenue recovery with rising margins and materially better leverage indicates operational recovery and a stronger earnings base. Improved balance-sheet metrics increase strategic flexibility to invest or execute M&A over a multi-month horizon.
Bears Say
Weak Free Cash Flow And Cash ConversionSignificantly weaker FCF and low cash conversion reduce internally available funds for capex, dividends, and acquisitions. Over 2–6 months this constrains financial flexibility and heightens dependence on external financing for growth initiatives or unexpected needs.
Margins Well Below Prior Peak And VolatilePersistent margin gap versus prior peaks and recent volatility suggest structural mix, pricing, or cost pressures. Lower sustainable margins constrain long-term returns and limit the company's ability to convert revenue gains into durable profit expansion.
High Absolute Debt BurdenElevated absolute debt increases interest and refinancing risk and reduces capacity for large discretionary spending. Even with better ratios, high nominal leverage limits resilience in downturns and can impede strategic agility over the medium term.
Sartorius Stedim Biotech News
0RG8 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest share price was €149.70 and its highest was €223.20 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €17.46B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Apr 23, 2026 which is in 55 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Feb 03, 2026. The company reported €1.12 earnings per share for the quarter, missing the consensus estimate of €1.264 by -€0.144.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.26.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.12 in its last earnings report, missing expectations of €1.264. Following the earnings report the stock price went up 3.365%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in GB:0RG8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
0RG8 Stock 12 Month Forecast
Average Price Target
€235.86
▲(34.01% Upside)
Technical Analysis
Options Prices
Currently, No data available
---